(AOF) – Seven abstracts, four of which including recent data, highlighting the new data of the programs pre-clinical and clinical food allergy DBV Technologies have been accepted in the Congress of digital of the European Academy Of Allergy and Clinical Immunology (EAACI), from 6 to 8 June 2020. The oral interventions and virtual posters will be available on the website of the EAACI for the conference attendees from Saturday, 6 June.
“The data that we present this year at the Congress digital EAACI highlight the potential applications of immunotherapy by means epicutaneous within populations of patients, as well as new insights on the cellular pathways that hold promise for the identification of biomarkers,” said Pharis Mohideen, M. D., medical director of DBV Technologies.
“These presentations highlight the breadth of the research conducted by DBV on the science and impact of food allergies in the context of our commitment to improve the lives of patients with potential treatments innovative as immunotherapy by means epicutaneous. Our drug candidate for the primary, Viaskin Peanut, is currently under review by the FDA. We are looking forward to make the experimental treatment available to patients as quickly as possible, if it were to be approved. ”
AOF – MORE INFORMATION